An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function
Apr 30, 2025
―
Esk-001
Hepatic Impairment
Phase I
Recruiting
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
Apr 22, 2025
―
Open-Label Esk-001, Blinded Esk-001
Psoriasis, Plaque Psoriasis, Psoriasis (Pso), Moderate Psoriasis, Severe Psoriasis
Phase III
Recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Jan 27, 2025
―
Apremilast, Esk-001
Plaque Psoriasis
Phase III
Active Not Recruiting
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
Sep 07, 2024
―
Apremilast, Esk-001
Plaque Psoriasis
Phase III
Active Not Recruiting
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Aug 14, 2024
―
Esk-001
Sle
Phase II
Active Not Recruiting
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
Jun 29, 2023
―
Esk-001
Plaque Psoriasis
Phase II
Active Not Recruiting
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
Feb 02, 2023
―
Esk-001
Plaque Psoriasis
Phase II
Completed
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
Oct 12, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Alumis Inc. (ALMS) have in its pipeline
ALMS is currently developing the following drugs: Esk-001, Esk-001, Open-Label Esk-001, Blinded Esk-001. These drug candidates are in various stages of clinical development as the company works toward FDA approval.